About Heidelberg Pharma
Heidelberg Pharma AG provides non-GLP pre-clinical drug discovery and development services. These include a full profiling program for small molecules and biologicals, with a variety of cell-based assays, in vivo animal models for cancer and inflammatory disease, DMPK analysis in rodents and organ distribution studies using radiolabeled compounds. With our skilled scientific staff we are able to offer short turn-around-time, a customized service and scientific and technical advice as needed.
Heidelberg Pharma AG works on the discovery and early development of conjugates that consist of a humanized or fully human monoclonal antibody, coupled via a specific linker molecules to a highly potent toxin. Such ADCs present the next generation of anti-cancer therapeutics, following the successful introduction of various antibody therapies against specific tumor targets.
© 2013 BioRN Cluster Management GmbH • All Rights Reserved • Contact & Legal Notice